Equillium's average Accounts Receivable for the
three
months ended in Dec. 2024 was $0.00 Mil. Equillium's Revenue for the
three
months ended in Dec. 2024 was $4.39 Mil.
Hence, Equillium's Days Sales Outstanding for the
three
months ended in Dec. 2024 was 0.00.
The historical rank and industry rank for Equillium's Days Sales Outstanding or its related term are showing as below:
EQ'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.17 Med: 33.24 Max: 65.73
Current: 40.96
During the past 8 years, Equillium's highest Days Sales Outstanding was 65.73. The lowest was 33.17. And the median was 33.24.
EQ's Days Sales Outstanding is ranked better than 77.27% of 849
companies
in the Biotechnology industry
Industry Median: 72.85
vs EQ: 40.96
Equillium's Days Sales Outstanding
declined
from Dec. 2023 (37.17) to Dec. 2024 (0.00).
Equillium Days Sales Outstanding Historical Data
The historical data trend for Equillium's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Equillium's Days Sales Outstanding
For the Biotechnology subindustry, Equillium's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equillium's Days Sales Outstanding Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Equillium's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Equillium's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equillium (NAS:EQ) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Equillium Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Equillium's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EQ has been successfully added to your 